Subscribe
shutterstock_281684060_mark_van_scyoc
Mark Van Scyoc / Shutterstock.com
18 November 2020AmericasRory O'Neill

Third Circuit under fire over FTC v AbbVie ruling

The US Federal Trade Commission and AbbVie both want a federal appeals court to rehear a lawsuit accusing the drug company of quashing competition through sham patent litigation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
FTC’s $448m AbbVie win overturned
2 October 2020   A US appeals court has cancelled a $448 million antitrust bill for AbbVie, in a blow for the US Federal Trade Commission.
Americas
AbbVie and Besins to pay FTC $448m in sham litigation case
2 July 2018   Pharmaceutical companies AbbVie and Besins Healthcare have been ordered to pay the US Federal Trade Commission $448 million for using “sham litigation” to block access to generic versions of a testosterone drug.
Americas
AbbVie says bar for ‘sham litigation’ is too low
3 June 2021   AbbVie has again urged the US Supreme Court to save it from claims of filing sham litigation to block competition for testosterone treatment AndroGel.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
FTC’s $448m AbbVie win overturned
2 October 2020   A US appeals court has cancelled a $448 million antitrust bill for AbbVie, in a blow for the US Federal Trade Commission.
Americas
AbbVie and Besins to pay FTC $448m in sham litigation case
2 July 2018   Pharmaceutical companies AbbVie and Besins Healthcare have been ordered to pay the US Federal Trade Commission $448 million for using “sham litigation” to block access to generic versions of a testosterone drug.
Americas
AbbVie says bar for ‘sham litigation’ is too low
3 June 2021   AbbVie has again urged the US Supreme Court to save it from claims of filing sham litigation to block competition for testosterone treatment AndroGel.

More on this story

Americas
FTC’s $448m AbbVie win overturned
2 October 2020   A US appeals court has cancelled a $448 million antitrust bill for AbbVie, in a blow for the US Federal Trade Commission.
Americas
AbbVie and Besins to pay FTC $448m in sham litigation case
2 July 2018   Pharmaceutical companies AbbVie and Besins Healthcare have been ordered to pay the US Federal Trade Commission $448 million for using “sham litigation” to block access to generic versions of a testosterone drug.
Americas
AbbVie says bar for ‘sham litigation’ is too low
3 June 2021   AbbVie has again urged the US Supreme Court to save it from claims of filing sham litigation to block competition for testosterone treatment AndroGel.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent